Medetomidine-Laced Opioids Trigger Severe Withdrawal Crisis in Jails Nationwide

When Lillian was booked into a rural Pennsylvania jail, her body was already rebelling. She couldn't stop vomiting. As she showered and changed into her jail uniform, "brain zaps" kept destabilizing her, electrical disruptions that made standing nearly impossible. The corrections officer watching her had to grab her repeatedly to keep her from hitting the concrete floor.

Lillian was withdrawing from fentanyl laced with medetomidine, a veterinary tranquilizer used to immobilize rhinoceroses that has infiltrated the illicit opioid supply over the past two years. The drug causes excruciating, complicated withdrawal symptoms that often begin within hours of a person's last dose, and many correctional facilities remain dangerously ill-prepared to treat them.

"It was hell," said Lillian, who asked to use a pseudonym because of stigma in her community. She received only ibuprofen and Pepto-Bismol during her withdrawal. "I'm genuinely amazed I didn't die."

A New Frontier of Withdrawal Severity

Medetomidine withdrawal represents a significant escalation in the challenges facing jails and prisons nationwide. The syndrome can include life-threatening strokes and heart attacks, requiring complex treatment protocols that combine oral and intravenous medications—some so heavily controlled they are typically only available in intensive care unit settings.

The Centers for Disease Control and Prevention reported in April that medetomidine has been detected in drug samples across all 20 sentinel surveillance sites, with highest prevalence in the Northeast and lowest in the West. The drug, also called "dex" for its chemical cousin dexmedetomidine, has seen detections surge 3,000% between 2023 and 2025, from 247 samples to over 8,000.

Jails already face significant challenges safeguarding prisoners experiencing opioid withdrawal. Strained resources, understaffing, and lack of protocols mean deaths related to unmanaged withdrawal have surfaced in lawsuits across the country. These deaths are preventable—multiple effective, FDA-approved medications exist for treating opioid use disorder and withdrawal symptoms.

Pittsburgh's Model: Collaboration and Resources

About an hour from where Lillian was incarcerated, Chris experienced the same medetomidine withdrawal syndrome at the Allegheny County Jail in Pittsburgh—but with dramatically different results. Upon arrival, he received Ativan and phenobarbital, medications that can alleviate severe withdrawal symptoms.

"I was grateful to get that, because I didn't think that was something that they would do for you in the county jail," Chris recalled. He was offered a comfortable bed in the medical processing area. "That was the last thing that I remembered before I woke up in the hospital a few days later."

Withdrawal from medetomidine had caused him to have a heart attack.

Pittsburgh, one of the cities hardest hit by medetomidine adulteration, has developed unique preparedness through direct collaboration between jail medical staff and academic researchers. Elizabeth Ferro, director of addiction medicine for Allegheny County Jail, worked with Dr. Michael Lynch at the University of Pittsburgh Medical Center, who has been actively researching medetomidine withdrawal treatment. When Ferro noticed people arriving with unusually severe symptoms, Lynch invited her to attend his webinars on emerging treatment protocols.

The Allegheny County Jail has expanded access to medication-assisted treatment significantly over the past few years, thanks partly to advocacy from Bethany Hallam, a county council member who experienced withdrawal during her own incarceration, and Stuart Fisk, a nurse practitioner who helped establish Prevention Point Pittsburgh, the city's oldest harm reduction organization.

The Medicaid Exclusion Problem

Federal law prohibits Medicaid from covering medications for people in jail, meaning treatment often comes directly from county budgets—a politically contentious expense. Hallam has had to push back against arguments that withdrawal medications are too costly or carry diversion risks.

Medications like buprenorphine and methadone can treat both opioid use disorder and withdrawal symptoms. When Hallam was incarcerated in 2017, non-pregnant prisoners received nothing for withdrawal management. "It was like a cold turkey detox," she recalled. Through sustained advocacy, the jail first began offering Sublocade, an extended-release injectable medication, and has since expanded to additional options.

A position paper from the National Commission on Correctional Health Care emphasizes the importance of offering a range of FDA-approved medications to people in jail with opioid use disorder. Research consistently shows that medication access improves mortality outcomes both during incarceration and after release, when overdose risk spikes dramatically.

Detection Challenges

Rapid urine toxicology panels are not designed to detect medetomidine. Instead, medical staff often confirm its presence by observing whether symptoms continue even after patients receive medications that usually provide relief. Dr. Lynch, the Pittsburgh researcher, recalled seeing patients in severe distress starting in fall 2024: "They would come in and they'd be shaky, sweaty, nauseated, their heart rates and blood pressures would start to go up—the kind of stuff that looked like it could be really bad opioid withdrawal, but more severe and much faster in onset."

Dr. Kevin Fiscella, a physician at the University of Rochester who helped create withdrawal protocols for U.S. jails, noted that many facilities already stock clonidine, a blood pressure medication that serves as an important tool for treating medetomidine withdrawal—though often at much higher doses than typically used. He recommends jails become "much more aggressive in starting treatment" with medications like buprenorphine to quickly clarify whether medetomidine is involved.

A National Preparedness Gap

Despite Department of Justice guidance stating that jails refusing medications to patients with existing prescriptions violate the Americans with Disabilities Act, a national survey found that fewer than half of jails offer any medication for opioid use disorder. The guidance does not specifically protect patients without existing prescriptions—the same population likely to experience severe withdrawal upon intake.

A randomized controlled trial comparing jails that adopted National Commission on Correctional Health Care accreditation standards—which require medication access—to control facilities found that accreditation significantly reduces jail mortality. But accreditation remains entirely voluntary.

"It's very difficult for them to finance this care, and yet they're constitutionally obligated to provide it," said Dr. Marcella Alsan, a physician and economist at Harvard who co-authored the study. "Sheriffs themselves are being put in a very difficult position, and the counties themselves are being put in a very, very difficult position."

The National Sheriffs' Association has formally opposed the Federal Medicaid Inmate Exclusion Policy, writing that denying federal benefits to presumed innocent individuals "without due process of law, is a violation of their constitutional rights."

The Human Cost

Chris, the Pittsburgh jail patient who received appropriate medical intervention for his medetomidine withdrawal, showed how quickly the situation can turn fatal without sustained support. One week after being interviewed for this story, he was arrested again while experiencing withdrawal and taken immediately to the hospital, where he suffered a second heart attack. After five days in an induced coma intended to help preserve his heart and brain, he showed small signs of recovery when removed from life support. But ultimately his heart gave out, and he died earlier this month.

Dr. Fiscella hopes the dire symptoms of medetomidine withdrawal will serve as a wake-up call. "I would like to see this be a wake-up call for all jails to begin treating opioid use disorder seriously," he said.

As medetomidine continues spreading across the country, the gap between well-resourced facilities like Allegheny County Jail and underfunded rural facilities like the one where Lillian was held threatens to widen. Ferro said she has received just one inquiry from a rural jail about unusually severe withdrawal symptoms. She offered to consult on treatment protocols. They never followed up.